vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and ENNIS, INC. (EBF). Click either name above to swap in a different company.
ENNIS, INC. is the larger business by last-quarter revenue ($100.2M vs $83.5M, roughly 1.2× BillionToOne, Inc.). ENNIS, INC. runs the higher net margin — 10.8% vs 6.8%, a 4.0% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 0.4%). ENNIS, INC. produced more free cash flow last quarter ($15.7M vs $6.5M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
ENNIS, INC. (ticker EBF) is a leading North American provider of printed business products and related services. Its offerings include custom business forms, pressure-sensitive labels, marketing collateral, promotional items, and branded packaging, serving clients across retail, healthcare, financial services, and small business segments.
BLLN vs EBF — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $100.2M |
| Net Profit | $5.7M | $10.8M |
| Gross Margin | 69.9% | 31.9% |
| Operating Margin | 11.5% | 15.0% |
| Net Margin | 6.8% | 10.8% |
| Revenue YoY | 117.4% | 0.4% |
| Net Profit YoY | 138.3% | 6.1% |
| EPS (diluted) | $0.10 | $0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $100.2M | ||
| Q3 25 | $83.5M | $98.7M | ||
| Q2 25 | — | $97.2M | ||
| Q1 25 | — | $92.7M | ||
| Q4 24 | $45.1M | $99.8M | ||
| Q3 24 | $38.4M | $99.0M | ||
| Q2 24 | — | $103.1M | ||
| Q1 24 | — | $97.4M |
| Q4 25 | — | $10.8M | ||
| Q3 25 | $5.7M | $13.2M | ||
| Q2 25 | — | $9.8M | ||
| Q1 25 | — | $9.0M | ||
| Q4 24 | $-11.5M | $10.2M | ||
| Q3 24 | $-14.9M | $10.3M | ||
| Q2 24 | — | $10.7M | ||
| Q1 24 | — | $10.1M |
| Q4 25 | — | 31.9% | ||
| Q3 25 | 69.9% | 30.5% | ||
| Q2 25 | — | 31.1% | ||
| Q1 25 | — | 29.5% | ||
| Q4 24 | 57.1% | 29.3% | ||
| Q3 24 | 52.6% | 30.1% | ||
| Q2 24 | — | 30.0% | ||
| Q1 24 | — | 28.4% |
| Q4 25 | — | 15.0% | ||
| Q3 25 | 11.5% | 12.5% | ||
| Q2 25 | — | 13.7% | ||
| Q1 25 | — | 13.0% | ||
| Q4 24 | 17.0% | 13.1% | ||
| Q3 24 | -32.9% | 13.3% | ||
| Q2 24 | — | 13.3% | ||
| Q1 24 | — | 13.3% |
| Q4 25 | — | 10.8% | ||
| Q3 25 | 6.8% | 13.3% | ||
| Q2 25 | — | 10.1% | ||
| Q1 25 | — | 9.7% | ||
| Q4 24 | -25.5% | 10.2% | ||
| Q3 24 | -38.8% | 10.4% | ||
| Q2 24 | — | 10.4% | ||
| Q1 24 | — | 10.4% |
| Q4 25 | — | $0.42 | ||
| Q3 25 | $0.10 | $0.51 | ||
| Q2 25 | — | $0.38 | ||
| Q1 25 | — | $0.34 | ||
| Q4 24 | $-1.13 | $0.39 | ||
| Q3 24 | $-1.47 | $0.40 | ||
| Q2 24 | — | $0.41 | ||
| Q1 24 | — | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $31.3M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $304.8M |
| Total Assets | $327.5M | $354.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $31.3M | ||
| Q3 25 | $195.2M | $31.9M | ||
| Q2 25 | — | $32.6M | ||
| Q1 25 | — | $72.5M | ||
| Q4 24 | $191.5M | $68.6M | ||
| Q3 24 | — | $122.6M | ||
| Q2 24 | — | $123.7M | ||
| Q1 24 | — | $110.9M |
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $51.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $304.8M | ||
| Q3 25 | $-239.5M | $305.4M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | — | $302.0M | ||
| Q4 24 | $-251.7M | $297.7M | ||
| Q3 24 | $-242.9M | $358.4M | ||
| Q2 24 | — | $354.4M | ||
| Q1 24 | — | $349.8M |
| Q4 25 | — | $354.3M | ||
| Q3 25 | $327.5M | $361.8M | ||
| Q2 25 | — | $361.7M | ||
| Q1 25 | — | $348.9M | ||
| Q4 24 | $302.1M | $346.1M | ||
| Q3 24 | — | $406.8M | ||
| Q2 24 | — | $406.2M | ||
| Q1 24 | — | $399.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $16.4M |
| Free Cash FlowOCF − Capex | $6.5M | $15.7M |
| FCF MarginFCF / Revenue | 7.7% | 15.7% |
| Capex IntensityCapex / Revenue | 8.8% | 0.7% |
| Cash ConversionOCF / Net Profit | 2.42× | 1.52× |
| TTM Free Cash FlowTrailing 4 quarters | — | $42.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $16.4M | ||
| Q3 25 | $13.8M | $10.5M | ||
| Q2 25 | — | $8.0M | ||
| Q1 25 | — | $12.8M | ||
| Q4 24 | — | $18.2M | ||
| Q3 24 | — | $11.8M | ||
| Q2 24 | — | $23.1M | ||
| Q1 24 | — | $16.6M |
| Q4 25 | — | $15.7M | ||
| Q3 25 | $6.5M | $9.0M | ||
| Q2 25 | — | $6.6M | ||
| Q1 25 | — | $11.1M | ||
| Q4 24 | — | $17.5M | ||
| Q3 24 | — | $10.7M | ||
| Q2 24 | — | $20.6M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | — | 15.7% | ||
| Q3 25 | 7.7% | 9.2% | ||
| Q2 25 | — | 6.8% | ||
| Q1 25 | — | 12.0% | ||
| Q4 24 | — | 17.6% | ||
| Q3 24 | — | 10.8% | ||
| Q2 24 | — | 20.0% | ||
| Q1 24 | — | 15.3% |
| Q4 25 | — | 0.7% | ||
| Q3 25 | 8.8% | 1.4% | ||
| Q2 25 | — | 1.4% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | — | 1.1% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 1.7% |
| Q4 25 | — | 1.52× | ||
| Q3 25 | 2.42× | 0.80× | ||
| Q2 25 | — | 0.81× | ||
| Q1 25 | — | 1.41× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | — | 1.15× | ||
| Q2 24 | — | 2.16× | ||
| Q1 24 | — | 1.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
EBF
Segment breakdown not available.
